Saturday, 31 October 2026European Markets

BENETEAU And TRIGANO Have A High Dividend Yield And Return On Equity In The Recreational Vehicles Industry.

Loading stream...

(vianews) - beneteau (ben.pa) is among this list of stock assets with the highest dividend rate and return on equity on the recreational vehicles industry.

financial asset price forward dividend yield return on equity
beneteau (ben.pa) €15.08 2.8% 15.44%
trigano (tri.pa) €136.80 2.58% 19.15%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. beneteau (ben.pa)

2.8% forward dividend yield and 15.44% return on equity

bénéteau s.a. designs, manufactures, and sells boats and leisure homes in france and internationally. it provides boats under the beneteau, jeanneau, lagoon, prestige, four winns, scarab, wellcraft, excess, and delphia brand names; and leisure homes under the irm, o'hara, and coco sweet brand names. the company also offers bandofbaots.com, a community services platform for purchase and sale of new or used boats; lease purchase, credit, and insurance services through sgb finance; and inventory and retail finance solutions. bénéteau s.a. was founded in 1884 and is headquartered in saint gilles croix de vie, france. bénéteau s.a. operates as a subsidiary of beri 21 s.a.

earnings per share

as for profitability, beneteau has a trailing twelve months eps of €1.25.

pe ratio

beneteau has a trailing twelve months price to earnings ratio of 12.06. meaning, the purchaser of the share is investing €12.06 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.44%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, beneteau's stock is considered to be oversold (<=20).

yearly top and bottom value

beneteau's stock is valued at €15.08 at 17:40 est, way below its 52-week high of €17.44 and way above its 52-week low of €9.43.

more news about beneteau.

2. trigano (tri.pa)

2.58% forward dividend yield and 19.15% return on equity

trigano s.a., together with its subsidiaries, engages in the design, manufacture, marketing, and sale of leisure vehicles for individuals and professionals in europe. it offers camping cars, caravans, motorhomes, trailers, and outdoor habitats. the company also provides mobiles homes, spare parts, and accessories, as well as leisure financing services. it offers its products through dealer networks and distributors, as well as through its online sales site, triganostore.com. trigano s.a. was founded in 1935 and is based in paris, france.

earnings per share

as for profitability, trigano has a trailing twelve months eps of €13.98.

pe ratio

trigano has a trailing twelve months price to earnings ratio of 9.79. meaning, the purchaser of the share is investing €9.79 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.15%.

yearly top and bottom value

trigano's stock is valued at €136.80 at 17:40 est, below its 52-week high of €140.80 and way higher than its 52-week low of €73.70.

volume

today's last reported volume for trigano is 4007 which is 78.84% below its average volume of 18941.

sales growth

trigano's sales growth for the current quarter is 27.5%.

more news about trigano.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com